0001209191-21-017590.txt : 20210303 0001209191-21-017590.hdr.sgml : 20210303 20210303215532 ACCESSION NUMBER: 0001209191-21-017590 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RASMUSSEN HENRIK S MD CENTRAL INDEX KEY: 0001271905 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38582 FILM NUMBER: 21712413 MAIL ADDRESS: STREET 1: 508 WRANGLER DRIVE, SUITE 100 CITY: COPPELL STATE: TX ZIP: 75019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allakos Inc. CENTRAL INDEX KEY: 0001564824 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454798831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-597-5002 MAIL ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001564824 Allakos Inc. ALLK 0001271905 RASMUSSEN HENRIK S MD 975 ISLAND DRIVE, SUITE 201 REDWOOD CITY CA 94065 0 1 0 0 Chief Medical Officer Common Stock 2021-03-03 4 S 0 1952 112.83 D 101819 D Common Stock 2021-03-03 4 S 0 20000 113.00 D 103771 D Common Stock 2021-03-03 4 M 0 20000 1.1625 A 123771 D Common Stock 2021-03-02 4 F 0 1316 117.82 D 103771 D Common Stock 2021-03-02 4 S 0 20000 117.32 D 105087 D Common Stock 2021-03-02 4 M 0 20000 1.1625 A 125087 D Common Stock 2021-03-01 4 S 0 20000 120.66 D 105087 D Common Stock 2021-03-01 4 M 0 20000 1.1625 A 125087 D Stock Option (Right to buy) 1.1625 2021-03-03 4 M 0 20000 0.00 D 2027-10-02 Common Stock 20000 332000 D Stock Option (Right to buy) 1.1625 2021-03-02 4 M 0 20000 0.00 D 2027-10-02 Common Stock 20000 352000 D Stock Option (Right to buy) 1.1625 2021-03-01 4 M 0 20000 0.00 D 2027-10-02 Common Stock 20000 372000 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $111.30 to $115.09 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $111.00 to $116.78 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of RSUs. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $115.85 to $121.83 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $117.445 to $126.76 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. On October 2, 2017, the Reporting Person was granted an option to purchase 392,000 ordinary shares pursuant to the Company's 2018 Equity Incentive Plan. The option vests as to one-fourth of the shares on October 2, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Henrik Rasmussen 2021-03-03